Product and Pipeline Assessment of the Global Orphan Drugs Market

Product and Pipeline Assessment of the Global Orphan Drugs Market

Attractive Market Lures Hundreds of Innovators, Large and Small

RELEASE DATE
27-Feb-2014
REGION
Asia Pacific
Research Code: ND7D-01-00-00-00
SKU: LS00120-AP-MR_16961
AvailableYesPDF Download

$3,950.00

Special Price $2,962.50 save 25 %

In stock
SKU
LS00120-AP-MR_16961

$3,950.00

$2,962.50save 25 %

DownloadLink
ENQUIRE NOW

Description

Breakthroughs in drug discovery have led to rich and competitive pipelines for rare diseases such as rare cancers as well as neurologic disorders and musculoskeletal disorders, among many other therapeutic areas. This research service provides a comprehensive global overview and analysis of global orphan drugs development, with an emphasis on the US market. Included are market background and global overview and analysis of drug development and regulatory activity by disease area and geography, detailed product and pipeline analysis of orphan drugs by therapeutic area and disease, and company analysis, including activity analysis and key companies to watch.

Table of Contents

Executive Summary

Executive Summary (continued)

Methodology and Scope

Market Background

Market Background (continued)

Market Background (continued)

NIH Orphan Diseases by Type

NIH Orphan Diseases by Type (continued)

Global Overview and Analysis

Global Overview and Analysis (continued)

Orphan Diseases with FDA-approved Therapies

Orphan Diseases with FDA-approved Therapies (continued)

Orphan Diseases with FDA-approved Therapies (continued)

Orphan Diseases with FDA-approved Therapies (continued)

Orphan Diseases with FDA-approved Therapies (continued)

Orphan Diseases with FDA-approved Therapies (continued)

Orphan Diseases with FDA-approved Therapies (continued)

FDA Approvals and Designations by Therapeutic Area

FDA Orphan Designations by Therapeutic Area

EMA Orphan Designations by Therapeutic Area

Count of US FDA and European EMA Orphan Drug Designations by Year

Count of US FDA and European EMA Orphan Drug Approvals by Year

Count of US FDA Orphan Drug Designations and Approvals by Year

Count of European EMA Orphan Drug Designations and Approvals by Year

Top Rare Cancer Designations

Top Rare Cancer Designations (continued)

Annual Count of FDA Rare Cancer Designations

Annual Count of FDA Pediatric Orphan Designations

Top Indications by Activity and Disease Overview

SCD—Orphan Drugs on the Market

SCD—Orphan Drugs in Development

SCD—Orphan Drugs in Development (continued)

MDS—Orphan Drugs on the Market

MDS—Orphan Drugs in Development

TTP—Orphan Drugs in Development

Top Indications by Activity and Disease Overview

PAH—Orphan Drugs on the Market

PAH—Orphan Drugs in Development

PAH—Orphan Drugs in Development (continued)

Calciphylaxis—Orphan Drugs in Development

Top Indications by Activity and Disease Overview

CF—Orphan Drugs on the Market

CF—Orphan Drugs in Development

CF—Orphan Drugs in Development (continued)

CF—Orphan Drugs in Development (continued)

CF—Orphan Drugs in Development (continued)

IPF—Orphan Drugs on the Market

IPF—Orphan Drugs in Development

IPF—Orphan Drugs in Development (continued)

IPF—Orphan Drugs in Development (continued)

Top Indications by Activity and Disease Overview

Fragile X Syndrome—Orphan Drugs in Development

HIBM—Orphan Drugs in Development

Top Indications by Activity and Disease Overview

SSc—Orphan Drugs in Development

EB—Orphan Drugs in Development

Top Indications by Activity and Disease Overview

Ped CD—Orphan Drugs on the Market

Ped CD—Orphan Drugs in Development

Ped CD—Orphan Drugs in Development (continued)

Ped UC—Orphan Drugs on the Market

Ped UC—Orphan Drugs in Development

Ped UC—Orphan Drugs in Development (continued)

Pouchitis—Orphan Drugs in Development

Top Indications by Activity and Disease Overview

T1D with Residual Beta-cell Function—Orphan Drugs in Development

T1D with Residual Beta-cell Function—Orphan Drugs in Development (continued)

Top Indications by Activity and Disease Overview

ARS—Orphan Drugs in Development

ARS—Orphan Drugs in Development (continued)

Top Indications by Activity and Disease Overview

RP—Orphan Drugs in Development

RP—Orphan Drugs in Development (continued)

Stargardt Disease—Orphan Drugs in Development

Uveitis—Orphan Drugs on the Market

Uveitis—Orphan Drugs in Development

Top Indications by Activity and Disease Overview

Behcet's Disease—Orphan Drugs in Development

Pipeline Analyses for Select Rare Diseases—Infectious/Parasitic Diseases

Top Indications by Activity and Disease Overview

CMV Infection—Orphan Drugs on the Market

CMV Infection—Orphan Drugs in Development

Malaria—Orphan Drugs on the Market

Malaria—Orphan Drugs in Development

Leishmaniasis—Orphan Drugs on the Market

Leishmaniasis—Orphan Drugs in Development

Top Indications by Activity and Disease Overview

Top Indications by Activity and Disease Overview (continued)

MPS—Orphan Drugs on the Market

MPS—Orphan Drugs in Development

MPS—Orphan Drugs in Development (continued)

Acromegaly—Orphan Drugs on the Market

Acromegaly—Orphan Drugs in Development

Urea Cycle Disorders—Orphan Drugs on the Market

Urea Cycle Disorders—Orphan Drugs in Development

NPC Disease—Orphan Drugs on the Market

NPC Disease—Orphan Drugs in Development

Pompe Disease—Orphan Drugs on the Market

Pompe Disease—Orphan Drugs in Development

Top Indications by Activity and Disease Overview

DMD—Orphan Drugs in Development

DMD—Orphan Drugs in Development (continued)

DMD—Orphan Drugs in Development (continued)

DMD—Orphan Drugs in Development (continued)

SMA—Orphan Drugs in Development

Top Indications by Activity and Disease Overview

ALS—Orphan Drugs in Development

ALS—Orphan Drugs in Development (continued)

ALS—Orphan Drugs in Development (continued)

ALS—Orphan Drugs in Development (continued)

HD—Orphan Drugs on the Market

HD—Orphan Drugs in Development

FA—Orphan Drugs in Development

Top Indications by Activity and Disease Overview

Pancreatic Cancer—Orphan Drugs on the Market

Pancreatic Cancer—Orphan Drugs in Development

Pancreatic Cancer—Orphan Drugs in Development (continued)

Pancreatic Cancer—Orphan Drugs in Development (continued)

Pancreatic Cancer—Orphan Drugs in Development (continued)

Pancreatic Cancer—Orphan Drugs in Development (continued)

Pancreatic Cancer—Orphan Drugs in Development (continued)

Glioma—Orphan Drugs on the Market

Glioma—Orphan Drugs in Development

Glioma—Orphan Drugs in Development (continued)

Glioma—Orphan Drugs in Development (continued)

Glioma—Orphan Drugs in Development (continued)

Glioma—Orphan Drugs in Development (continued)

AML—Orphan Drugs on the Market

AML—Orphan Drugs in Development

AML—Orphan Drugs in Development (continued)

AML—Orphan Drugs in Development (continued)

AML—Orphan Drugs in Development (continued)

AML—Orphan Drugs in Development (continued)

Top 20 Companies by Activity

Top Companies by Activity per Therapeutic Area

Top Earning Orphan Drugs

Select Recent Launches

Companies to Watch—Alexion Pharmaceuticals

Companies to Watch—BioMarin Pharmaceutical Inc.

Companies to Watch—Celgene Corporation

Companies to Watch—PTC Therapeutics

Companies to Watch—Spotlight on Innovation

Strategic Partnership Assessment

Strategic Partnership Assessment (continued)

Strategic Partnership Assessment (continued)

Conclusions and Recommendations

Legal Disclaimer

List of Rare Cancers in “Others”

List of Rare Cancers in “Others” (continued)

List of Rare Cancers in “Others” (continued)

The Frost & Sullivan Story

Value Proposition: Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
The global market for vaccines is estimated to be only 2-3% of the total pharmaceuticals market in 2014; however, this sector has been continuously experiencing a stellar growth rate of 10-15% per year versus the 5-7% seen in the overall market. Currently, the most commonly available vaccines are administered by injection, which makes mass immunization more costly and less safe, particularly in resource-poor developing countries. More than 120 new products are currently in the development pipeline, of which sixty hold significant importance to developing nations. The type of delivery system will predict which type of vaccine delivery will remain the most attractive (in terms of revenue) for stakeholders in the next 5 years. --BEGIN PROMO-- Analysis of the Global Vaccines Delivery Market
More Information
No Index Yes
Podcast No
Author Deborah Toscano
WIP Number ND7D-01-00-00-00
Is Prebook No